2-amino-9-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,7-dihydropurine-6,8-dione

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-amino-9-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,7-dihydropurine-6,8-dione
• 化学式: C₁₀H₁₃N₅O₅
• 分子量: 283.24
• InChiKey: HCAJQHYUCKICQH-YZNZAMEGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  150
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES
  申请人：Genoscience Pharma SAS

  公开号：EP3620164A1

  公开（公告）日：2020-03-11

  The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

  本发明涉及新型2-初级氨基-4-次级氨基喹啉衍生物，其制备方法，包含它们的药物组合物以及它们作为药物的用途。本发明的活性化合物可用作药物治疗和/或减少和/或预防纤维化和/或与纤维化相关疾病，或用作药物治疗和/或减少和/或预防自噬和/或与自噬相关疾病以及抑制自噬通量，或用于抑制蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）和/或与蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）相关疾病；但所述化合物不得用于治疗任何形式的癌症。
• [EN] FLOUROALKYL, FLOUROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS<br/>[FR] DÉRIVÉS FLUOROALKYLE, FLUOROALCOXY, PHÉNOXY, HÉTÉROARYLOXY, ALCOXY, ET AMINE 1,4-BENZOQUINONE POUR LE TRAITEMENT DE TROUBLES DU STRESS OXYDATIF
  申请人：BIOELECTRON TECH CORP

  公开号：WO2017106803A1

  公开（公告）日：2017-06-22

  Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

  披露的是一种用于治疗或抑制氧化应激紊乱的化合物及其使用方法，包括线粒体紊乱、能量加工障碍、神经退行性疾病和老年性疾病，或用于调节一个或多个能量生物标志物，正常化一个或多个能量生物标志物，或增强一个或多个能量生物标志物，其中所述化合物是生育酚醌衍生物。进一步披露了化合物、组合物和治疗或预防辐射暴露的方法。
• [EN] IMMUNOMODULATORY CONJUGATES<br/>[FR] CONJUGUÉS IMMUNOMODULATEURS
  申请人：ASCEND BIOPHARMACEUTICALS PTY LTD

  公开号：WO2013067597A1

  公开（公告）日：2013-05-16

  The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.

  本发明提供了一种免疫调节化合物，包括一种含有甘露糖的碳水化合物聚合物，其中该碳水化合物聚合物与至少一种免疫调节剂结合。本发明还提供了将该化合物用于免疫调节组合物、疫苗和基因治疗方法的用途，以及其制备方法。
• [EN] NAPHTHOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS<br/>[FR] DÉRIVÉS DE NAPHTOQUINONE POUR LE TRAITEMENT DE TROUBLES DU STRESS OXYDATIF
  申请人：PTC THERAPEUTICS INC

  公开号：WO2020252414A1

  公开（公告）日：2020-12-17

  Disclosed herein are naphthoquinone derivative compounds of the formula shown below, compositions thereof, and methods of using such compounds and compositions for treating or suppressing oxidative stress disorders and/or neurodegenerative disorders and/or for inhibiting ferroptosis.

  本文披露了下述结构式的萘醌衍生物化合物，以及这些化合物的组合物和使用这些化合物和组合物治疗或抑制氧化应激性疾病和/或神经退行性疾病和/或抑制铁死亡的方法。
• METABOLITE BIOMARKERS FOR THE DETECTION OF ESOPHAGEAL CANCER USING MS
  申请人：Raftery M. Daniel

  公开号：US20120107955A1

  公开（公告）日：2012-05-03

  Results of studies of nucleosides in biofluid specimens from patients with esophageal adenocarcinoma and related disorders have identified five biomarkers of the conditions: 1-methyladenosine, N 2 ,N 2 -dimethylguanosine, N 2 -methylguanosine, cytidine and uridine. In certain embodiments, methods of measuring these biomarkers and kits for measuring these biomarkers are provided.

  对食管腺癌患者和相关疾病生物体液样本中核苷的研究结果表明了这些疾病的五个生物标志物：1-甲基腺苷、N2,N2-二甲基鸟苷、N2-甲基鸟苷、胞嘧啶和尿苷。在某些实施例中，提供了测量这些生物标志物的方法和用于测量这些生物标志物的试剂盒。